|
February 9, 2010
|
| 12:01 EDT |  | JNJ |
| theflyonthewall.com: | Gilead to start talks on quad pill partnership, Bloomberg reports | | Gilead will start talks as soon as next week with Bristol-Myers Squibb (BMY) or Johnson & Johnson (JNJ) regarding a partnership for the company's four-drug combination AIDS pill, Gilead COO John Milligan said in an interview, according to Bloomberg. Milligan says Gilead was approached by a company about a partnership, but did not mention a company name. :theflyonthewall.com |
|
| 07:06 EDT |  | JNJ |
| theflyonthewall.com: | Chinese sovereign fund owns $9.6B in stock of U.S. companies, NY Times says | | China's sovereign wealth fund bought more than $9B of stock in U.S. companies last year, according to the New York Times. The $300B fund now owns shares of Apple (AAPL), Coca-Cola (KO), Johnson & Johnson (JNJ), Motorola (MOT), Visa (V), and other well-known American companies, the newspaper adds. Reference Link :theflyonthewall.com |
|
|
February 5, 2010
|
| 06:44 EDT | | JNJ |
|
|
February 3, 2010
|
| 09:53 EDT |  | JNJ |
|
|
February 2, 2010
|
| 08:36 EDT |  | JNJ |
|
|
February 1, 2010
|
| 10:36 EDT | | JNJ |
|
| 08:03 EDT | | JNJ |
| theflyonthewall.com: | Boston Scientific settles patent disputes with Johnson & Johnson | | Boston Scientific Corporation (BSX) announced the settlement of three patent disputes with Johnson & Johnson (JNJ). The disputes date back to 2003 and cover Boston Scientific's Jang patent and J&J's Palmaz and Gray patents, all of which involve intellectual property in the cardiovascular arena. Boston Scientific will make a $1.725B payment to J&J in connection with the settlement. Under the settlement, Boston Scientific will pay J&J $1B today and the balance on or before the first week of January 2011. The Company plans to post a $745M letter of credit, which will cover the $725M balance and interest. The payments will not have an appreciable impact on the Company's debt covenants. After the payments, the Company will still have significant liquidity under its credit facilities, and it continues to expect to refinance its 2011 debt maturities in the middle of this year. The Company expects to fund the $725M remaining balance from cash on hand, unless it refinances at an earlier date. :theflyonthewall.com |
|
|
January 29, 2010
|
| 07:56 EDT | | JNJ |
|
|
January 27, 2010
|
| 21:13 EDT | | JNJ |
| theflyonthewall.com: | Barrons.com sees five drug candidates boosting their company's sales in 2010 | | According to Decision Resources, drug companies could receive FDA approval for 50 new therapies this year with the potential to generate sales totaling $15B a year by 2015. Some drugs have the ability to shine above the others and boost the bottom lines of the companies that make them. Doctors and industry experts helped Barrons.com find five drug candidates that could hit the U.S. market in 2010, improving the treatment of serious illnesses. The list includes Novo Nordisk's (NVO) diabetes drug, Victoza, and Dendreon's (DNDN) prostate cancer therapy, Provenge. Then there's Vivus' (VVUS) obesity treatment, Qnexa, and Amgen's (AMGN) remedy for osteoporosis, Prolia. Finally, Johnson & Johnson (JNJ) and Bayer (BAYRY) hope to jointly market a blood thinner, Xarelto. Bottom-line: these five drugs could be what the doctor ordered for a sales-starved industry and investors looking for returns. Reference Link :theflyonthewall.com |
|
| 21:12 EDT | | JNJ |
|
| 08:08 EDT |  | JNJ |
|
|
January 26, 2010
|
| 16:15 EDT | | JNJ |
|
| 09:26 EDT | | JNJ |
| theflyonthewall.com: | Johnson & Johnson receives FDA clearance for marketing CARTO 3 System | | JNJ received FDA clearance for marketing the CARTO 3 System, the most advanced three-dimensional imaging technology for use by electrophysiologists in treating cardiac arrhythmias, commonly referred to as irregular heart rhythms. :theflyonthewall.com |
|
| 09:20 EDT | | JNJ |
|
| 09:19 EDT | | JNJ |
|
| 07:59 EDT |  | JNJ |
|
| 07:56 EDT | | JNJ |
| theflyonthewall.com: | Johnson & Johnson sees FY10 EPS $4.85-$4.95 vs. consensus of $4.94 | | :theflyonthewall.com |
|
| 07:55 EDT | | JNJ |
| theflyonthewall.com: | Johnson & Johnson reports Q4 EPS $1.02 vs. consensus of 97c | | Reports Q4 revenue $16.6B vs. consensus of $15.07B :theflyonthewall.com |
|
Subscribe for More Information